Literature DB >> 10826882

Solution structure of the human BTK SH3 domain complexed with a proline-rich peptide from p120cbl.

S R Tzeng1, Y C Lou, M T Pai, M L Jain, J W Cheng.   

Abstract

X-linked agammaglobulinemia (XLA), an inherited disease, is caused by mutations in the Bruton's tyrosine kinase (BTK). The absence of functional BTK leads to failure of B cell differentiation which incapacitates antibody production in XLA patients leading to, sometimes lethal, bacterial infections. Point mutation in the BTK gene that leads to deletion of C-terminal 14 aa residues of BTK SH3 domain was found in one patient family. To understand the role of BTK in B cell development, we have determined the solution structure of BTK SH3 domain complexed with a proline-rich peptide from the protein product of c-cbl protooncogene (p120cbl). Like other SH3 domains, BTK SH3 domain consists of five beta-strands packed in two beta-sheets forming a beta-barrel-like structure. The rmsd calculated from the averaged coordinates for the BTK SH3 domain residues 218-271 and the p120cbl peptide residues 6-12 of the complex was 0.87 A (+/-0.16 A) for the backbone heavy atoms (N, C, and Calpha) and 1.64 A (+/-0.16 A) for all heavy atoms. Based on chemical shift changes and inter-molecular NOEs, we have found that the residues located in the RT loop, n-Src loop and helix-like loop between beta4 and beta5 of BTK SH3 domain are involved in ligand binding. We have also determined that the proline-rich peptide from p120cbl binds to BTK SH3 domain in a class I orientation. These results correlate well with our earlier observation that the truncated BTK SH3 domain (deletion of beta4, beta5 and the helix-like loop) exhibits weaker affinity for the p120cbl peptide. It is likely that the truncated SH3 domain fails to present to the ligand the crucial residues in the correct context and hence the weaker binding. These results delineate the importance of the C-terminus in the binding of SH3 domains and also indicate that improper folding and the altered binding behavior of mutant BTK SH3 domain likely lead to XLA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10826882     DOI: 10.1023/a:1008376624863

Source DB:  PubMed          Journal:  J Biomol NMR        ISSN: 0925-2738            Impact factor:   2.835


  31 in total

1.  Solution structure of the Grb2 N-terminal SH3 domain complexed with a ten-residue peptide derived from SOS: direct refinement against NOEs, J-couplings and 1H and 13C chemical shifts.

Authors:  M Wittekind; C Mapelli; V Lee; V Goldfarb; M S Friedrichs; C A Meyers; L Mueller
Journal:  J Mol Biol       Date:  1997-04-11       Impact factor: 5.469

Review 2.  Protein modules and signalling networks.

Authors:  T Pawson
Journal:  Nature       Date:  1995-02-16       Impact factor: 49.962

3.  Signalling an interest.

Authors:  H Yu; S L Schreiber
Journal:  Nat Struct Biol       Date:  1994-07

Review 4.  Molecular basis for human immunodeficiencies.

Authors:  L Hammarström; M Gillner; C I Smith
Journal:  Curr Opin Immunol       Date:  1993-08       Impact factor: 7.486

5.  Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands.

Authors:  S Feng; C Kasahara; R J Rickles; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

6.  Regulatory intramolecular association in a tyrosine kinase of the Tec family.

Authors:  A H Andreotti; S C Bunnell; S Feng; L J Berg; S L Schreiber
Journal:  Nature       Date:  1997-01-02       Impact factor: 49.962

7.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.

Authors:  D Vetrie; I Vorechovský; P Sideras; J Holland; A Davies; F Flinter; L Hammarström; C Kinnon; R Levinsky; M Bobrow
Journal:  Nature       Date:  1993-01-21       Impact factor: 49.962

8.  Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.

Authors:  C I Smith; B Baskin; P Humire-Greiff; J N Zhou; P G Olsson; H S Maniar; P Kjellén; J D Lambris; B Christensson; L Hammarström
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

9.  Structural basis for the specific interaction of lysine-containing proline-rich peptides with the N-terminal SH3 domain of c-Crk.

Authors:  X Wu; B Knudsen; S M Feller; J Zheng; A Sali; D Cowburn; H Hanafusa; J Kuriyan
Journal:  Structure       Date:  1995-02-15       Impact factor: 5.006

10.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

Authors:  S Tsukada; D C Saffran; D J Rawlings; O Parolini; R C Allen; I Klisak; R S Sparkes; H Kubagawa; T Mohandas; S Quan
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

View more
  7 in total

1.  Quantitative relation between intermolecular and intramolecular binding of pro-rich peptides to SH3 domains.

Authors:  Huan-Xiang Zhou
Journal:  Biophys J       Date:  2006-08-04       Impact factor: 4.033

2.  Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia.

Authors:  S R Tzeng; M T Pai; F D Lung; C W Wu; P P Roller; B Lei; C J Wei; S C Tu; S H Chen; W J Soong; J W Cheng
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

3.  Competing modes of self-association in the regulatory domains of Bruton's tyrosine kinase: intramolecular contact versus asymmetric homodimerization.

Authors:  Alain Laederach; Kendall W Cradic; Kristine N Brazin; Jamillah Zamoon; D Bruce Fulton; Xin-Yun Huang; Amy H Andreotti
Journal:  Protein Sci       Date:  2002-01       Impact factor: 6.725

4.  Conformational snapshots of Tec kinases during signaling.

Authors:  Raji E Joseph; Amy H Andreotti
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

5.  Conserved patterns and interactions in the unfolding transition state across SH3 domain structural homologues.

Authors:  Cullen Demakis; Matthew C Childers; Valerie Daggett
Journal:  Protein Sci       Date:  2020-11-26       Impact factor: 6.993

6.  Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.

Authors:  Qi Wang; Erik M Vogan; Laura M Nocka; Connor E Rosen; Julie A Zorn; Stephen C Harrison; John Kuriyan
Journal:  Elife       Date:  2015-02-20       Impact factor: 8.140

7.  Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.

Authors:  Shruti Sharma; Natalie Galanina; Ailin Guo; Jimmy Lee; Sabah Kadri; Charles Van Slambrouck; Bradley Long; Weige Wang; Mei Ming; Larissa V Furtado; Jeremy P Segal; Wendy Stock; Girish Venkataraman; Wei-Jen Tang; Pin Lu; Yue Lynn Wang
Journal:  Oncotarget       Date:  2016-10-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.